fluorouracil has been researched along with tivozanib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cotreau, MM; de Vries, EG; den Hollander, MW; Eskens, FA; Esteves, B; Gietema, JA; Loos, WJ; Oldenhuis, CN; Strahs, AL; van Doorn, L | 1 |
Ball, HA; Benson, AB; Bridgewater, J; Chen, J; Eskens, FA; Keating, A; Kiss, I; Krivoshik, A; Sasse, C; Van Sant, C; Vossen, S | 1 |
2 trial(s) available for fluorouracil and tivozanib
Article | Year |
---|---|
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Phenylurea Compounds; Quinolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2015 |
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neuropilin-1; Organoplatinum Compounds; Phenylurea Compounds; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2016 |